Improving Methylphenidate Titration in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): A Randomized...

Area of Science:

• Pediatric Psychiatry
• Neurodevelopmental Disorders
• Pharmacological Treatments

Background:

• Rising methylphenidate (MPH) use in attention-deficit/hyperactivity disorder (ADHD) raises concerns.
• Placebo-controlled methylphenidate titration (PCT) shows promise in experimental settings for optimizing ADHD treatment.
• This study evaluates the clinical applicability of PCT in ADHD management.

Purpose of the Study:

• To assess if the benefits of PCT, including improved placebo response detection and symptom improvement, translate to clinical practice.
• To compare PCT with care as usual (CAU) in managing MPH treatment for children with ADHD.
• To evaluate the impact of PCT on MPH discontinuation and use of alternative pharmacological treatments.

Main Methods:

• Children aged 5-13 with ADHD were randomized to PCT or CAU.
• A 7-week randomized controlled trial was followed by a 6-month open-label follow-up.
• ADHD symptoms, medication use, and treatment satisfaction were assessed via parent, teacher, and physician ratings.

Main Results:

• PCT identified a higher rate of MPH non-responders compared to CAU.
• Significantly more children discontinued MPH and avoided other pharmacological treatments in the PCT group.
• No significant differences were observed in average MPH dose, ADHD symptom severity, or treatment satisfaction between groups.

Conclusions:

• PCT effectively identifies children who do not benefit from MPH, potentially reducing overtreatment.
• The findings support the use of PCT as a clinical tool for optimizing MPH therapy in ADHD.
• PCT aids in personalized methylphenidate treatment decisions for pediatric ADHD.